Monopar Therapeutics stock falls 7.5 percent on September 23

Monopar Therapeutics stock fell 7.50 percent to USD 89.38 in the latest quote at 4:00 p.m. ET on September 23, 2026. The clinical-stage biotechnology company is preparing two ALXN1840 presentations for the AASLD meeting from November 5 to November 9, 2026, according to Monopar Therapeutics.

Pipeline dates add a checkpoint

The company develops radiopharmaceuticals for advanced solid tumors and ALXN1840 for Wilson Disease. Its oncology pipeline includes MNPR-101-Zr for imaging and MNPR-101-Lu for radiotherapeutic treatment, while the November event gives investors a dated checkpoint for the Wilson Disease program.

The September 23 quote put Monopar's market capitalization at USD 598,761,983. The stock traded between USD 50.07 and USD 124.82 over the 52-week period, leaving the latest price 28.39 percent below the yearly high.

Quarterly loss beats consensus

MarketBeat reported that Monopar's Q2 2026 earnings released on August 12, 2026 showed EPS of negative USD 0.62, compared with a consensus loss of USD 0.64. The USD 0.02 per-share beat is modest, but it gives the valuation discussion a concrete operating reference while the company remains focused on clinical development.

Monopar also reported a Q2 2026 operating loss of USD 6,644,663 and a net loss of USD 5,313,300. Cash and cash equivalents stood at USD 52,757,766 on June 30, 2026, which is the key balance-sheet figure behind the financing runway for its clinical programs.

Stock trades below its yearly high

The latest quote was USD 89.38 on NASDAQ at 4:00 p.m. ET on September 23, 2026, down USD 7.25 from the previous close of USD 96.63. For investors, the combination of a 28.39 percent gap to the 52-week high and the November AASLD date makes clinical progress the central valuation checkpoint.